Data From INNOVIVE Pharmaceuticals' Oncology Drug Programs to Be Presented at the American Society of Hematology 48th Annual Mee

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Inv.Perp.Sel Hd	LSE:IVPH	London	Ordinary Share	GB00B1DQ6696	HEDGE FD SHS 1P

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
	0	0		N/A	0

Inv.Perp.Sel Hd (LSE:IVPH)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more Inv.Perp.Sel Hd Charts.

NEW YORK, Dec. 6 /PRNewswire-FirstCall/ -- INNOVIVE Pharmaceuticals, Inc. (OTC:IVPH) (BULLETIN BOARD: IVPH) announced that data supporting further development of the company's drug candidates INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec resistant chronic myelogenous leukemia, and INNO-305, a peptide immunotherapy for the treatment of acute myelogenous leukemia, will be presented at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition. The conference takes place December 9-12, 2006 at the Orange County Convention Center in Orlando, Florida. INNO-406 * Abstract #834: "Cyclosporin A, a P-gp Inhibitor, Augments the Anti-Central Nervous System Ph+ Leukemia Effects of INNO-406." Oral Presentation: Dec. 12 at 8:15am EST; Room 315 * Abstract #2178: "BH3 Mimetic Augments the Induction of Apoptosis by INNO-406, a Novel Bcr-Abl/Lyn Inhibitor, in Bcr-Abl+ Leukemic Cells." Poster Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 356-II * Abstract #2177: "Cell Death Mechanisms Induced by INNO-406, a Novel Tyrosine Kinase Inhibitor for Imatinib-Resistant Ph+ Leukemia." Poster Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 355-II * Abstract #2123: "CXCR4 Up-Regulation by Imatinib Mesylate Induces CML Cell Migration to Bone Marrow Stroma and Promotes Survival of Chemoresistant Quiescent CML Cells." Poster Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 301-II * Abstract #2167: "Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib." Poster Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 345-II * Abstract #2179: "The ATP Competitor INNO-406 (NS-187) Inhibits Proliferation and Survival of Mouse Cells Expressing Several Imatinib Mesylate Resistant Bcr/Abl Mutants and Cells from CML Patients." Poster Presentation: Dec. 10 from 9:00am to 8:00pm EST; Hall E1, Board 357-II INNO-305 * Abstract #3706: "CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells." Poster Presentation: Dec. 11 from 10:30am to 7:00pm EST; Hall E1, Board 935-III About INNO-406 INNO-406 (formerly known as NS-187) is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently in Phase I clinical studies. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25 to 55 times more potent than imatinib in vitro, and at least 10 times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 12 of 13 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer. About INNO-305 INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is in a Phase I clinical trial for the treatment of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) as well as patients with non-small cell lung cancer (NSCLC) and mesothelioma. INNO-305 is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells. It is believed that stimulating both types of T-cells may result in a more robust and ubiquitous immune response. About Innovive Pharmaceuticals INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has three drug programs in clinical development, INNO-406, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia. For additional information visit http://www.innovivepharma.com/. DATASOURCE: INNOVIVE Pharmaceuticals, Inc. CONTACT: Steve Kelly, President and CEO of INNOVIVE Pharmaceuticals, Inc., +1-212-716-1820; or Rachel Lipsitz, Media & Investor Relations, Porter Novelli Life Sciences, +1-619-849-5378, for INNOVIVE Pharmaceuticals, Inc. Web site: http://www.innovivepharma.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

IVPH Inv.Perp.Sel Hd